Vaxart, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VXRT research report →
Range $2 – $2
Price Chart
About the company
Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions.
- CEO
- Steven Lo
- IPO
- 1981
- Employees
- 65
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on VXRT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $80.42M
- P/E
- 2.82
- PEG
- 0.01
- P/S
- 0.44
- P/B
- 1.21
- EV/EBITDA
- 1.43
- Div Yield
- 0.00%
- Gross Margin
- 99.30%
- Op Margin
- 16.63%
- Net Margin
- 16.02%
- ROE
- 35.14%
- ROIC
- 55.35%
Latest fiscal year · YoY change
- Revenue
- $237.26M+726.7%
- Gross Profit
- $237.26M+726.7%
- Op Income
- $18.07M
- Net Income
- $16.33M+124.4%
- EPS
- $0.07+150.0%
- OCF Growth
- +117.2%
- FCF Growth
- +116.7%
- 52W High
- $0.84
- 52W Low
- $0.30
- 50D MA
- $0.43
- 200D MA
- $0.57
- Beta
- 1.06
- RSI (14)
- 27
- Avg Volume
- 289.00K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Vaxart said Q3 progress was driven by its large BARDA-funded Phase 2b COVID trial, European norovirus patent protection, and continued efforts to secure partnerships and funding, while cash runway remains a key constraint.· November 6, 2026
- Phase 2b COVID-19 trial remains the main operational focus, with efficacy and safety data now expected by midyear 2027.
- Vaxart ended Q3 with $65.5 million in cash, cash equivalents and short-term investments, with runway projected into Q2 2027.
- Q3 revenue was $10.6 million, down from $72.4 million a year ago; net loss was $17.7 million, or $0.07 per share.
- The company said its European norovirus patent now extends protection through at least 2036 across 13 European nations.
- Management emphasized ongoing partnership talks, but said timing of additional data releases and deals depends on BARDA review and external lab processing.
Vaxart reported third-quarter revenue of $10.6 million versus $72.4 million in Q3 2025. R&D expense was $22.8 million compared with $75.9 million a year ago, G&A expense was $5.1 million versus $4.3 million, and net loss was $17.7 million, or $0.07 per share, versus a net loss of $8.1 million, or $0.04 per share, in the prior-year period. The company ended Q3 with $65.5 million in cash, cash equivalents and short-term investments and said that, under current assumptions, this funds operations into Q2 2027. Management said the full Phase 2b COVID trial readout is expected by midyear 2027, and the remaining $25 million Lincoln Park equity line is available as a flexible source of capital at Vaxart’s discretion; if fully used, it could potentially extend runway into 2028.
Steven Lo framed the quarter as one of clinical progress, governance changes, and portfolio validation. He stressed that the company’s priority is executing the approximately 5,000-participant Phase 2b COVID trial, preserving optionality on financing, and pursuing partnerships without sacrificing long-term value. His tone was measured but optimistic, repeatedly pointing to BARDA support, the potential Sanofi opt-in, and the idea that progress in COVID could help open doors for other programs like flu and norovirus.
Jeroen Grasman focused on liquidity, burn discipline, and funding flexibility. He said the company ended Q3 with $65.5 million in cash, expects runway into Q2 2027, and continues to evaluate ways to extend that runway through nondilutive funding and selective use of the $25 million Lincoln Park equity line. He also noted that Vaxart generated $0.5 million from share sales under the April 2026 share purchase agreement through September 30, 2026, and said the company is keeping corporate spending tightly controlled while prioritizing the BARDA-funded COVID study and the wholly owned norovirus program.
The biggest recurring question was timing: investors pressed for why the Phase 2b readout shifted from the first half of 2027 to mid-2027, and management said the schedule is driven by protocol observation windows, lab processing, and BARDA review rather than a company decision. Shareholders also asked about more detailed sentinel data; management said neither Vaxart nor any external party has that underlying immunogenicity data yet, and disclosure depends on BARDA approval after external lab analysis. Other questions centered on norovirus partnering, the European patent, and dilution; management said interest exists but biopharma diligence is slow, and that the company is using the equity line only sparingly while seeking nondilutive capital first.
The positive case from this call is that Vaxart believes it is de-risking its platform through a large federally funded trial, with a clean 12-month sentinel safety result already in hand and full readout still targeted for midyear 2027. The company also highlighted meaningful pipeline value from a European norovirus patent through 2036, a peer-reviewed H5N1 ferret study showing 100% protection, and ongoing interest from potential partners.
The main risks are timing and financing: full COVID data has slipped to mid-2027, key detailed data have not yet been seen even by management, and release timing depends on outside labs and BARDA approval. Cash remains limited, with runway projected only into Q2 2027 under current assumptions, and management acknowledged broader biopharma headwinds, slower diligence, and the possibility that partner discussions for norovirus may not lead to a deal.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 98.3%
- Shares Outstanding
- 243.70M
- Float Shares
- 239.66M
of shares held by institutions
5 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Kingswood Wealth Advisors, LLC | 10.01K | 0 |
| Hantz Financial Services, Inc. | 8.30K | ▲ 8.30K |
| Ascentis Independent Advisors | 2.00K | ▲ 2.00K |
| Org Partners LLC | 2.00K | 0 |
| Archer Investment Corp | 15 | 0 |
Held by 5 ETFs
Biggest fund positions in VXRT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 16, 26 | Bono Raquel C. | other | 157,400 |
| Oct 16, 26 | Bono Raquel C. | other | 78,800 |
| Oct 16, 26 | Bono Raquel C. | other | 0 |
| Jul 16, 26 | Finney Kevin | other | 39,400 |
| Jul 16, 26 | Finney Kevin | other | 78,700 |
| Jul 16, 26 | BREITMEYER JAMES B | other | 8,315 |
| Jul 16, 26 | BREITMEYER JAMES B | other | 16,610 |
| Jul 16, 26 | HERON ELAINE J | other | 39,400 |
| Jul 16, 26 | HERON ELAINE J | other | 78,700 |
| Jul 16, 26 | Watson W. Mark | other | 39,400 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VXRT coverage
Recent articles, reports, and earnings notes.
No research on VXRT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VXRT report →Vaxart Q3 Earnings Call Highlights
marketbeat.com · Nov 8
Vaxart, Inc. (VXRT) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 8
Vaxart to Host Stockholder Fireside Chat on November 6 at 4:30 p.m. ET
globenewswire.com · Oct 29
Vaxart Announces Publication of Preclinical Study Demonstrating 100% Protection Against a Lethal Dose of H5N1 Avian Flu in a Ferret Challenge Model
globenewswire.com · Oct 8
Vaxart Highlights Oral Vaccine Platform, COVID Trial Progress at H.C. Wainwright Conference
marketbeat.com · Sep 15
Vaxart to Present at the H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com · Sep 8
Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology
globenewswire.com · Aug 26
Vaxart Q2 Earnings Call Highlights
marketbeat.com · Aug 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.